Roche launches new Elevidys study after feedback from European regulator [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
The therapy for duchenne muscular dystrophy (DMD), for which Roche partners ?with American Sarepta Therapeutics, had failed to win backing from the European Medicines Agency (EMA) last year after coming under scrutiny following two patient deaths tied to the treatment. • ?The phase III ?study aims to generate additional placebo-controlled data required for a regulatory re-submission with EMA. • Elevidys ?is currently approved in nine countries for ambulatory boys with a confirmed DMD mutation, including in the United States, ?which had ?temporarily ordered a pause ?in shipments last July. • ?DMD is a rare, inherited disease that mostly affects boys and causes muscles to weaken steadily over time. • The study will span more than 72 weeks and evaluate the efficacy and safety of Elevidys compared to placebo ?in around 100 early ambulatory boys ?with DMD. The primary endpoint ?is the change in ?the so-called "time to rise" from the floor ?velocity. • "Our confidence is rooted in
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) PlatformBusiness Wire
- Is Chugai Pharmaceutical (TSE:4519) Still Attractively Priced After Its Strong Multi Year Run [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Launches Foundayo: A Novel Oral GLP-1 Weight Management Therapy [TheStreet.com]TheStreet.com
- C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates [Seeking Alpha]Seeking Alpha
- Two more pharmaceutical companies, Abbvie and Genentech, to officially launch on TrumpRx [CBS News]CBS News